司美格鲁肽:“王冠”又添明珠

健识局
Oct 21

口服减重药的记录刷新了。9月23日,一项发表于《新英格兰医学杂志》的3期临床试验结果显示:每日一次的25 mg口服司美格鲁肽片,遵医嘱服用64周后,实现平均体重16.6%的降幅1*。这意味着:诺和诺德又一次跑到减重竞速赛的最前列。今年上半年,司美格鲁肽以175亿美元的销售额超越“全球药王”的帕博利珠单抗,眼看就要上演“新王登基”的戏码。但司美格鲁肽原本独占的减重赛道却被同行紧迫追赶,GLP-1双...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10